Unione Europea - italiano - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leucemia, mieloide - agenti antineoplastici - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

medivis s.r.l. - trifluridina - trifluridina

Unione Europea - italiano - EMA (European Medicines Agency)

les laboratoires servier - trifluridina, tipiracil hydrochloride - neoplasie colorettali - agenti antineoplastici - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sanofi s.r.l. - idoxuridina - idoxuridina

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

recordati ag - pasireotidum - soluzione iniettabile - pasireotidum 0.3 mg ut pasireotidi diaspartas, mannitolum, acidum tartaricum, natrii hydroxidum q.s. ad ph, aqua ad iniectabile ad solutionem pro 1 ml. - behandlung von malattia di cushing - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

recordati ag - pasireotidum - soluzione iniettabile - pasireotidum 0.6 mg ut pasireotidi diaspartas, mannitolum, acidum tartaricum, natrii hydroxidum q.s. ad ph, aqua ad iniectabile ad solutionem pro 1 ml. - behandlung von malattia di cushing - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

recordati ag - pasireotidum - soluzione iniettabile - pasireotidum 0.9 mg ut pasireotidi diaspartas, mannitolum, acidum tartaricum, natrii hydroxidum q.s. ad ph, aqua ad iniectabile ad solutionem pro 1 ml. - behandlung von malattia di cushing - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

recordati ag - pasireotidum - polvere e soluzione per sospensione iniettabile - praeparatio sicca: pasireotidum 20 mg ut pasireotidi pamoas, poly(lactidum-co-glycolidum), pro vitro. solvens: mannitolum, carmellosum natricum corresp. natrium 1.5 mg, poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 2 ml. - akromegalie, morbo di cushing - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

recordati ag - pasireotidum - polvere e soluzione per sospensione iniettabile - praeparatio sicca: pasireotidum 40 mg ut pasireotidi pamoas, poly(lactidum-co-glycolidum), pro vitro. solvens: mannitolum, carmellosum natricum corresp. natrium 1.5 mg, poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 2 ml. - akromegalie, morbo di cushing - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

recordati ag - pasireotidum - polvere e soluzione per sospensione iniettabile - praeparatio sicca: pasireotidum 60 mg ut pasireotidi pamoas, poly(lactidum-co-glycolidum), pro vitro. solvens: mannitolum, carmellosum natricum corresp. natrium 1.5 mg, poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 2 ml. - akromegalie, morbo di cushing - synthetika